company background image
NOX

Noxopharm ASX:NOX Stock Report

Last Price

AU$0.21

Market Cap

AU$62.8m

7D

-10.4%

1Y

-63.6%

Updated

25 May, 2022

Data

Company Financials
NOX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NOX Stock Overview

Noxopharm Limited, a drug development company, engages in the research and development of drugs for the treatment of cancer and prevention of septic shock in Australia and internationally.

Noxopharm Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Noxopharm
Historical stock prices
Current Share PriceAU$0.21
52 Week HighAU$0.81
52 Week LowAU$0.20
Beta1.36
1 Month Change-33.85%
3 Month Change-40.28%
1 Year Change-63.56%
3 Year Change-65.32%
5 Year Change-43.42%
Change since IPO16.22%

Recent News & Updates

Shareholder Returns

NOXAU BiotechsAU Market
7D-10.4%0.5%-1.2%
1Y-63.6%-8.0%-0.009%

Return vs Industry: NOX underperformed the Australian Biotechs industry which returned -8% over the past year.

Return vs Market: NOX underperformed the Australian Market which returned -0% over the past year.

Price Volatility

Is NOX's price volatile compared to industry and market?
NOX volatility
NOX Average Weekly Movement11.7%
Biotechs Industry Average Movement9.9%
Market Average Movement9.3%
10% most volatile stocks in AU Market16.3%
10% least volatile stocks in AU Market4.2%

Stable Share Price: NOX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: NOX's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015n/aGisela Mautnerhttps://www.noxopharm.com

Noxopharm Limited, a drug development company, engages in the research and development of drugs for the treatment of cancer and prevention of septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries.

Noxopharm Fundamentals Summary

How do Noxopharm's earnings and revenue compare to its market cap?
NOX fundamental statistics
Market CapAU$62.83m
Earnings (TTM)-AU$11.24m
Revenue (TTM)AU$6.04m

10.4x

P/S Ratio

-5.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NOX income statement (TTM)
RevenueAU$6.04m
Cost of RevenueAU$12.59m
Gross Profit-AU$6.55m
Other ExpensesAU$4.68m
Earnings-AU$11.24m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.038
Gross Margin-108.45%
Net Profit Margin-185.98%
Debt/Equity Ratio0%

How did NOX perform over the long term?

See historical performance and comparison
New valuation analysis is now available for all ASX stocks. This is in beta.

Future Growth

How is Noxopharm forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


16.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Noxopharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Noxopharm performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


8.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NOX is currently unprofitable.

Growing Profit Margin: NOX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NOX is unprofitable, but has reduced losses over the past 5 years at a rate of 8.6% per year.

Accelerating Growth: Unable to compare NOX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NOX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.7%).


Return on Equity

High ROE: NOX has a negative Return on Equity (-33.51%), as it is currently unprofitable.


Financial Health

How is Noxopharm's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: NOX's short term assets (A$25.1M) exceed its short term liabilities (A$2.3M).

Long Term Liabilities: NOX's short term assets (A$25.1M) exceed its long term liabilities (A$192.6K).


Debt to Equity History and Analysis

Debt Level: NOX is debt free.

Reducing Debt: NOX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NOX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NOX has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 22.1% each year.


Dividend

What is Noxopharm current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate NOX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NOX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NOX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NOX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NOX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Gisela Mautner

2.58yrs

Tenure

Dr. Gisela Mautner serves as Chief Medical Officer at Noxopharm Limited since October 2019 and serves as its Chief Executive Officer and Executive Managing Director since February 01, 2022. Dr. Mautner has...


Leadership Team

Experienced Management: NOX's management team is considered experienced (2.5 years average tenure).


Board Members

Experienced Board: NOX's board of directors are considered experienced (4.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.8%.


Top Shareholders

Company Information

Noxopharm Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Noxopharm Limited
  • Ticker: NOX
  • Exchange: ASX
  • Founded: 2015
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: AU$62.831m
  • Shares outstanding: 292.24m
  • Website: https://www.noxopharm.com

Number of Employees


Location

  • Noxopharm Limited
  • Tower A, The Zenith
  • Level 20
  • Chatswood
  • New South Wales
  • 2067
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/25 00:00
End of Day Share Price2022/05/25 00:00
Earnings2021/12/31
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.